Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473694 | 0.89 | ADORA2B (0.56) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL1001096 | 0.83 | ADORA2B (0.67) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL2687515 | 0.82 | ADORA2B (0.46) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL3479031 | 0.82 | ADORA2B (0.67) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL29494961 | 0.81 | ADORA2B (1.00) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL1948396 | 0.78 | ADORA2B (0.69) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL1223271 | 0.77 | ADORA2B (1.00) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL24787659 | 0.77 | ADORA2B (0.63) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL12094031 | 0.77 | ADORA2B (0.53) | ADORA2BADORA3ADORA2AKDM4EMEN1 | |
| SCHEMBL24786705 | 0.77 | ADORA2B (0.63) | ADORA2BADORA3ADORA2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| EP-2405917-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-04-23 | — | — | EP | disclosed |
| EP-2405917-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2014-04-23 | — | — | EP | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| WO-2010103547-A2 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA3 3/4885ADORA2A 1/4885 |
| US-20150087643-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA2B 4/4885ADORA3 3/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.